AIM ImmunoTech Inc. — Director's Dealing 2015

Dec 14, 2015

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HEMISPHERX BIOPHARMA INC (HEB)
CIK: 0000946644
Period of Report: 2015-12-09

Reporting Person: CARTER WILLIAM A (Director, CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2015-12-09	Options	$2.71	J	73728	Disposed	2020-12-22	Common Stock (73728)	Direct
2015-12-09	Options	$4.03	J	10000	Disposed	2022-04-13	Common Stock (10000)	Direct
2015-12-09	Options	$2.6	J	320000	Disposed	2024-12-08	Common Stock (320000)	Direct
2015-12-09	Options	$0.29	J	100000	Disposed	2022-06-06	Common Stock (100000)	Direct
2015-12-09	Options	$0.25	J	150000	Disposed	2023-08-02	Common Stock (150000)	Direct
2015-12-09	Warrants	$0.51	J	491196	Disposed	2019-02-01	Common Stock (491196)	Direct

Footnotes

F1: As Section 5.1 in the 2009 Equity Incentive Plan states that there is an aggregate limitation of 3 million shares per person, these options and warrants were forfeited to comply with this limitation.